N C Levitt

2.0k total citations
14 papers, 1.0k citations indexed

About

N C Levitt is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, N C Levitt has authored 14 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 7 papers in Oncology and 3 papers in Genetics. Recurrent topics in N C Levitt's work include DNA Repair Mechanisms (4 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Glioma Diagnosis and Treatment (2 papers). N C Levitt is often cited by papers focused on DNA Repair Mechanisms (4 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Glioma Diagnosis and Treatment (2 papers). N C Levitt collaborates with scholars based in United Kingdom, United States and Switzerland. N C Levitt's co-authors include Ian D. Hickson, Nicholas Proudfoot, Daniel Briggs, A Gil, Sally L. Davies, Leonard Wu, Adrian L. Harris, David Propper, Jeremy Braybrooke and Trivadi S. Ganesan and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

N C Levitt

14 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N C Levitt United Kingdom 11 847 291 236 119 84 14 1.0k
A. Lehmann United Kingdom 11 907 1.1× 222 0.8× 196 0.8× 114 1.0× 57 0.7× 19 1.0k
Serena Fernandez Italy 9 916 1.1× 343 1.2× 530 2.2× 84 0.7× 52 0.6× 9 1.1k
Dimitri Semizarov United States 11 792 0.9× 237 0.8× 240 1.0× 115 1.0× 27 0.3× 17 972
Irene Collins United States 17 990 1.2× 118 0.4× 147 0.6× 125 1.1× 79 0.9× 24 1.1k
Marie‐Jeanne Pillaire France 20 1.1k 1.3× 294 1.0× 367 1.6× 112 0.9× 60 0.7× 33 1.3k
Giuseppina Giglia‐Mari France 16 1.1k 1.4× 242 0.8× 261 1.1× 206 1.7× 52 0.6× 20 1.3k
Jen‐Wei Huang United States 15 1.4k 1.7× 364 1.3× 443 1.9× 204 1.7× 62 0.7× 19 1.5k
Brandi L. Mahaney Canada 7 924 1.1× 182 0.6× 327 1.4× 70 0.6× 66 0.8× 7 1.0k
Etsuko Shibata United States 19 1.2k 1.4× 281 1.0× 367 1.6× 177 1.5× 41 0.5× 24 1.3k
Prabha Sarangi United States 14 1.1k 1.3× 142 0.5× 291 1.2× 199 1.7× 85 1.0× 15 1.2k

Countries citing papers authored by N C Levitt

Since Specialization
Citations

This map shows the geographic impact of N C Levitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N C Levitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N C Levitt more than expected).

Fields of papers citing papers by N C Levitt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N C Levitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N C Levitt. The network helps show where N C Levitt may publish in the future.

Co-authorship network of co-authors of N C Levitt

This figure shows the co-authorship network connecting the top 25 collaborators of N C Levitt. A scholar is included among the top collaborators of N C Levitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N C Levitt. N C Levitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
Mehta, Shaveta, Nick Hughes, Francesca M. Buffa, et al.. (2011). Assessing Early Therapeutic Response to Bevacizumab in Primary Breast Cancer Using Magnetic Resonance Imaging and Gene Expression Profiles. JNCI Monographs. 2011(43). 71–74. 37 indexed citations
3.
Khan, Omar, Michalis Michael, Ian Olver, et al.. (2008). A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. British Journal of Cancer. 98(10). 1614–1618. 45 indexed citations
4.
Levitt, N C, David Propper, Srinivasan Madhusudan, et al.. (2005). Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer. British Journal of Cancer. 93(1). 60–69. 5 indexed citations
5.
Braybrooke, Jeremy, N C Levitt, Simon Joel, et al.. (2003). Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression.. PubMed. 9(13). 4682–8. 22 indexed citations
6.
Levitt, N C & Ian D. Hickson. (2002). Caretaker tumour suppressor genes that defend genome integrity. Trends in Molecular Medicine. 8(4). 179–186. 77 indexed citations
7.
Levitt, N C, Ferry A.L.M. Eskens, Kenneth J. O’Byrne, et al.. (2001). Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.. PubMed. 7(7). 1912–22. 106 indexed citations
8.
Wu, Leonard, Sally L. Davies, N C Levitt, & Ian D. Hickson. (2001). Potential Role for the BLM Helicase in Recombinational Repair via a Conserved Interaction with RAD51. Journal of Biological Chemistry. 276(22). 19375–19381. 243 indexed citations
9.
Hickson, Ian D., S L Davies, N C Levitt, et al.. (2001). Role of the Bloom's syndrome helicase in maintenance of genome stability. Biochemical Society Transactions. 29(2). 201–204. 36 indexed citations
10.
Propper, David, N C Levitt, Kenneth J. O’Byrne, et al.. (2000). Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer. British Journal of Cancer. 82(11). 1776–1782. 2 indexed citations
11.
Propper, David, Jeremy Braybrooke, N C Levitt, et al.. (2000). Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. British Journal of Cancer. 82(11). 1759–1763. 14 indexed citations
12.
Propper, David, Jeremy Braybrooke, D.J. Taylor, et al.. (1999). Phase I trial of the selective mitochondrial toxin MKT 077 in chemo-resistant solid tumours. Annals of Oncology. 10(8). 923–927. 103 indexed citations
13.
Levitt, N C, et al.. (1991). A pause site for RNA polymerase II is associated with termination of transcription.. The EMBO Journal. 10(7). 1833–1842. 100 indexed citations
14.
Levitt, N C, Daniel Briggs, A Gil, & Nicholas Proudfoot. (1989). Definition of an efficient synthetic poly(A) site.. Genes & Development. 3(7). 1019–1025. 254 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. Lehmann Breakdown of academic impact, for papers by Serena Fernandez Breakdown of academic impact, for papers by Dimitri Semizarov Breakdown of academic impact, for papers by Irene Collins Breakdown of academic impact, for papers by Marie‐Jeanne Pillaire Breakdown of academic impact, for papers by Giuseppina Giglia‐Mari Breakdown of academic impact, for papers by Jen‐Wei Huang Breakdown of academic impact, for papers by Brandi L. Mahaney Breakdown of academic impact, for papers by Etsuko Shibata Breakdown of academic impact, for papers by Prabha Sarangi
Rankless by CCL
2026